Abbott Laboratories (ABT)
| Market Cap | 183.08B |
| Revenue (ttm) | 40.33B |
| Net Income (ttm) | 5.63B |
| Shares Out | 1.74B |
| EPS (ttm) | 3.21 |
| PE Ratio | 32.79 |
| Forward PE | 21.89 |
| Dividend | $2.20 (2.09%) |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 5,722,299 |
| Open | 106.46 |
| Previous Close | 105.96 |
| Day's Range | 104.66 - 107.14 |
| 52-Week Range | 89.67 - 121.64 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 122.30 (+16.21%) |
| Earnings Date | Jul 18, 2024 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2023, ABT's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.70 billion, a decrease of -17.44%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $122.3, which is an increase of 16.21% from the latest price.
News
Abbott must pay $95 million in premature infant formula trial, jury finds
A jury on Friday found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $95 mill...
Should You Pick Abbott Stock At $105 After A Solid Q2?
Abbott (NYSE: ABT) recently reported its Q2 results, with revenues and earnings exceeding our expectations. The company reported revenue of $10.4 billion and earnings of $1.14 on a per-share and adjus...
Abbott Laboratories Posts Big Drop in COVID-19 Testing Revenue
Shares of Abbott Laboratories (ABT) declined in intraday trading Thursday as the healthcare products maker's sales of COVID-19 tests slumped with the pandemic ending.
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday.
Abbott plans marketing push for glucose monitors beyond diabetes
Abbott Laboratories will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for the U.S. launch of its glucose monitoring d...
Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product
Abbott Laboratories (NYSE: ABT) faced a 3.0% decline in stock price this morning despite reporting a strong second quarter and raising its full-year guidance. Meanwhile, CEO Robert B.
Abbott Labs CEO on Q2 earnings
Abbott Labs CEO Robert Ford joins 'Squawk on the Street' to discuss what's driving the company's double-digit gains in the quarter, his take on the 2024 election, and more.
Abbott raises annual profit forecast as strong medical device sales power quarterly beat
Abbott Laboratories raised its annual profit forecast on Thursday and beat Wall Street estimates for second-quarter earnings, buoyed by strong sales of its cardiac and diabetes devices.
Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance
Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digi...
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.
Down 7% This Year Will Abbott Stock See Higher Levels Post Q2 Results?
Abbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly alignin...
3 buys and a bail: Merck, Abbott, Cigna, and Zoom
Gina Sanchez, chief market strategist at Lido Advisors, joins CNBC's 'The Exchange' to discuss four stocks: Merck, Abbott, Cigna, and Zoom.
Abbott trial on preterm infant formula linked to NEC disease kicks off this week
Similac baby formula maker Abbott is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease...
Abbott faces trial over claims that preterm infant formula caused dangerous disease
Similac baby formula maker Abbott is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease...
How Does The Current Fall In Abbott Stock Compare With The One During 2008 Recession?
Abbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its peak level of over $140 seen in December 2021. In comparison, its peer Boston Scientific stock (NYSE: BSX) has seen a nearly ...
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.
Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health
Eight health centers across the U.S. participate in Innovation Incubator to find new ways to integrate healthy food into clinical care Now in its second year, the goal of the Innovation Incubator is t...
New Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
Abbott Declares 402nd Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 14, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
FDA approves two new Abbott over-the-counter continuous glucose monitors
Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription. A CGM is a small sensor that pokes through the skin and tracks a person's gluco...
US FDA clears Abbott's continuous glucose monitors for over-the-counter use
Abbott said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use.
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
Abbott's consumer biowearable, Lingo™, is designed for general consumers who are looking to improve their overall health and wellness Libre Rio™ is designed for adults with Type 2 diabetes who do not ...
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has t...
Calls Of The Day: Eli Lilly, UnitedHealth Group, Abbott Labs and Johnson & Johnson
The Investment Committee discuss the latest Calls of the Day.
Drugmaker Abbott India posts Q4 profit rise on higher sales
Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.